Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KRRO 
Frequency Therapeutics Inc (KRRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: KRRO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $92.33
1 Year Target Price $92.33
| 6 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.18% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 288.86M USD | Price to earnings Ratio - | 1Y Target Price 92.33 |
Price to earnings Ratio - | 1Y Target Price 92.33 | ||
Volume (30-day avg) 10 | Beta - | 52 Weeks Range 10.29 - 98.00 | Updated Date 09/15/2025 |
52 Weeks Range 10.29 - 98.00 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.74 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1863.15% |
Management Effectiveness
Return on Assets (TTM) -28.65% | Return on Equity (TTM) -58.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 237134176 | Price to Sales(TTM) 45.99 |
Enterprise Value 237134176 | Price to Sales(TTM) 45.99 | ||
Enterprise Value to Revenue 37.75 | Enterprise Value to EBITDA -5.6 | Shares Outstanding 9390900 | Shares Floating 5744040 |
Shares Outstanding 9390900 | Shares Floating 5744040 | ||
Percent Insiders 6.17 | Percent Institutions 97.35 |
Upturn AI SWOT
Frequency Therapeutics Inc
Company Overview
History and Background
Frequency Therapeutics, Inc. was founded in 2014. It is a biotechnology company focused on developing therapies to activate progenitor cells within the body to restore healthy tissue. The company's primary focus has been on hearing loss.
Core Business Areas
- Hearing Loss Therapeutics: Frequency Therapeutics is focused on developing regenerative medicines for hearing loss by activating progenitor cells within the inner ear.
Leadership and Structure
David Lucchino is the CEO. The company has a board of directors and various management teams overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- FX-322: FX-322 is Frequency Therapeutics' lead drug candidate for sensorineural hearing loss (SNHL). Currently, there is no approved therapy to reverse SNHL, giving FX-322 potential. No significant revenue has been generated from FX-322 since it is under investigation. Competitors include companies exploring gene therapies and other regenerative approaches for hearing loss. Lack of successful data of FX-322 during Phase 2 has pushed Frequency to stop operations on FX-322
Market Dynamics
Industry Overview
The hearing loss therapeutics market is large and growing, driven by an aging population and noise-induced hearing damage. It is characterized by a high unmet need for regenerative therapies.
Positioning
Frequency Therapeutics aimed to be a leader in regenerative medicine for hearing loss. However, after the phase 2 trial it is unclear if they can become a leader. Competitors are working on gene therapies, stem cell therapies, and other innovative approaches.
Total Addressable Market (TAM)
The global hearing loss therapeutics market is estimated to be worth billions of dollars. Frequency Therapeutics aimed to capture a significant share of this market with its regenerative approach. TAM has not been calculated given the FX-322 data from phase 2 trial.
Upturn SWOT Analysis
Strengths
- Innovative regenerative medicine approach
- Experienced leadership team (although recently restructured)
- Strong intellectual property portfolio
Weaknesses
- Reliance on a single lead product candidate (FX-322)
- High cash burn rate
- Clinical trial risks and uncertainty regarding regulatory approval
- Unsuccessful Phase 2 data
Opportunities
- Potential to address a large unmet medical need
- Expansion to other therapeutic areas beyond hearing loss
- Partnerships with larger pharmaceutical companies
- Advancements in regenerative medicine technologies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Changing market dynamics
- Funding challenges
Competitors and Market Share
Key Competitors
- LLY (Eli Lilly)
Competitive Landscape
Frequency Therapeutics faced an uphill battle against larger, more established pharmaceutical companies with greater resources. It depended on its regenerative medicine approach to differentiate itself.
Growth Trajectory and Initiatives
Historical Growth: Frequency Therapeutics' growth has been dependent on the progress of FX-322. Unsuccessful data has led to a dramatic decrease in growth.
Future Projections: Future projections are highly uncertain given the challenges with FX-322. Company is considering alternatives for FX-322.
Recent Initiatives: Frequency Therapeutics has been actively conducting clinical trials for FX-322. The company is also exploring other potential therapeutic areas.
Summary
Frequency Therapeutics is a biotechnology company that has taken a hit due to the data readout of its FX-322 drug. The company's fate is uncertain due to their dependence on this drug. The company needs to look out for its cash position if they will still perform R&D. The fundamentals of Frequency Therapeutics are weak and the company needs to look into better approaches to help those who have hearing loss.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst reports
- Market research reports
- SEC filings
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. The analysis is based on publicly available information and may not be complete or accurate. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Frequency Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2023-11-06 | CEO, President & Director Dr. Ram Aiyar MBA, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 92 | Website https://www.korrobio.com |
Full time employees 92 | Website https://www.korrobio.com | ||
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.